Skip to main content

Table 2 Associations of immune check point receptor expression in TILs with neoadjuvant chemotherapy response as calculated “MD Anderson Cancer Center (MDACC) Residual Cancer Burden Index” in TNBC patients

From: TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

Expression in
TILs (>%1)
N = 61 (%) pCR(+) vs (−)a P- value Class 0/I vs II/IIIa P- value Class 0/I/II vs IIIa P- value
PD-L1 (+) vs other 29/57 (50.9%) 5/9 (56%) vs 24/47 (51%) 0.999 6/11 (55%) vs 23/45 (51%) 0.999 19/31 (61%) vs 10/25 (40%) 0.188
PD1 (+) vs other 37/61 (62%) 5/9 (56%) vs 32/51 (63%) 0.721 7/13 (54%) vs 30/47 (64%) 0.739 19/34 (56%) vs 18/26 (69%) 0.432
LAG3 (+) vs other 16/61 (26%) 2/9 (22%) vs14/51 (28%) 0.999 3/13 (23%) vs 13/47 (28%) 0.999 11/34 (32%) vs 5/26 (19%) 0.378
PD1&LAG3 (+) vs other 14/61 (23%) 2/9 (22%) vs 12/51 (24%) 0.999 3/13 (23%) vs 11/47 (23%) 0.999 9/34 (26%) vs 5/26 (19%) 0.555
TIM3 (+) vs other 42/61 (69%) 2/9 (22%) vs 39/51 (77%) 0.003 6/13 (46%) vs 35/47 (75%) 0.108 25/34 (74%) vs 16/26 (62%) 0.478
PD1&TIM3 (+) vs other 31/61 (51%) 2/9 (22%) vs 28/51 (55%) 0.145 4/13 (31%) vs 26/47 (55%) 0.209 16/34 (47%) vs 14/26 (54%) 0.794
CTLA-4 (+) vs other 50/61 (82%) 9/9 (100%) vs 40/51 (78%) 0.189 12/13 (92%) vs 37/47 (79%) 0.427 30/34 (88%) vs 19/26 (73%) 0.182
CTLA-4b(+) vs other 43/61 (70.5%) 9/9 (100%) vs 33/51 (65%) 0.047 12/13 (92%) vs 30/47 (64%) 0.084 26/34 (77%) vs 16/26 (62%) 0.334
PD1&CTLA-4 (+) vs other 33/61 (54%) 5/9 (56%) vs 27/51 (53%) 0.999 7/13 (54%) vs 25/47 (53%) 0.999 18/34 (53%) vs 14/26 (54%) 0.999
  1. Tumor infiltrating (stromal) lymphocytes (=TILs)
  2. a One patient with a residual tumor in the lymphovascular area has been excluded
  3. bCTLA-high expression: > 15%&any moderate or strong staining if < 15%
\